Details of the Drug

General Information of Drug (ID: DMGECIJ)

Drug Name
Blinatumomab
Synonyms AMG 103; Blincyto
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [1]
B-cell acute lymphoblastic leukaemia 2B33.3 Approved [2]
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [3]
Affected Organisms
Humans and other mammals
ATC Code
L01FX07: Blinatumomab
L01FX: Other monoclonal antibodies and antibody drug conjugates
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Sequence
DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVS
GIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGG
SGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPG
DGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYW
GQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGL
EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYC
LDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSS
VSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQ
QWSSNPLTFGAGTKLELKHHHHHH
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 2.11 +/- 1.42 hours [4]
Metabolism
The drug is metabolized via the catabolic pathways []
Vd
The volume of distribution (Vd) of drug is 4.52 L []
Cross-matching ID
UNII
4FR53SIF3A
DrugBank ID
DB09052
TTD ID
D0K4RK
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Modulator [5]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute lymphoblastic leukaemia
ICD Disease Classification 2A85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Blinatumomab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Blinatumomab and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [6]
Oliceridine DM6MDCF Moderate Decreased metabolism of Blinatumomab caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [7]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Blinatumomab and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [8]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Blinatumomab and Cannabidiol. Epileptic encephalopathy [8A62] [9]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Blinatumomab and Polyethylene glycol. Irritable bowel syndrome [DD91] [10]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Blinatumomab and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [11]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Blinatumomab and Idelalisib. Mature B-cell leukaemia [2A82] [12]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Blinatumomab and Siponimod. Multiple sclerosis [8A40] [6]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Blinatumomab and Ocrelizumab. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Blinatumomab and Ozanimod. Multiple sclerosis [8A40] [9]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Blinatumomab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [14]
⏷ Show the Full List of 11 DDI Information of This Drug

References

1 ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
2 Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Hum Vaccin Immunother. 2019;15(3):594-602.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
8 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
11 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
12 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
13 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
14 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]